ISRCTN15070952进行中（未招募）3 期
A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma
Greater Glasgow and Clyde Healthboard and University of Glasgow0 个研究点目标入组 69 人开始时间: 2014年12月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 12/07/2019:
- •1. R0 resected stage I, II, III or IV SBA
- •2. No evidence of residual or metastatic disease at laparotomy or on CT/MRI imaging of chest, abdomen and pelvis
- •3. Patients must be registered and randomised within 14 weeks of surgery and commence chemotherapy within 16 weeks of surgery
- •4. ECOG Performance Status of 0 or 1
- •5. Absolute neutrophil account = 1.5 x109/l
- •6. Platelet count = 100 x 109/l
- •7. Haemoglobin =90 g/l (previous transfusion is allowed)
- •8. AST and ALT = 2.5 x upper limit of normal (ULN). (At least one of ALT or AST MUST be performed)
- •9. Creatinine clearance > 50 ml/min (calculated by Cockcroft Gault or Wright equation) or measured by EDTA
- •10. Serum bilirubin = 1.5 x ULN
- •11. Signed and dated informed consent indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment
- •12. Age = 16 years
- •13.Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other trial procedures
- •Previous participant inclusion criteria:
- •1. R0 resected stage I, II or III SBA
- •2. No evidence of residual or metastatic disease at laparotomy or on CT/MRI imaging of chest, abdomen and pelvis
- •3. Patients must be registered and randomised within 12 weeks of surgery and commence chemotherapy within 14 weeks of surgery
- •4. ECOG Performance Status of 0 or 1
- •5. Absolute neutrophil account = 1.5 x109/l
- •6. Platelet count = 100 x 109/l
- •7. Haemoglobin =90 g/l (previous transfusion is allowed)
- •8. AST and ALT = 2.5 x upper limit of normal (ULN). (At least one of ALT or AST MUST be performed)
- •9. Creatinine clearance > 50 ml/min (calculated by Cockcroft Gault or Wright equation) or measured by EDTA
- •10. Serum bilirubin = 1.5 x ULN
- •11. Signed and dated informed consent indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment
- •12. Age = 16 years
- •13.Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other trial procedures
排除标准
- •Current participant exclusion criteria as of 12/07/2019:
- •1. Non-adenocarcinoma histology of small bowel tumour which includes but is not confined to lymphoma, GIST, carcinoid or other neuroendocrine tumour, squamous carcinoma, melanoma or sarcoma.
- •2. Adenocarcinoma arising in the appendix or colorectum
- •3. Previous neo-adjuvant chemo(radio)therapy for SBA
- •4. Clinically significant cardiovascular disease (i.e. active or < 12 months since cerebrovascular accident, myocardial infarction, unstable angina, New York Heart Association [NYHA] grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension)
- •5. Pregnancy/lactation or of child bearing potential and not using medically approved contraception. (Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential)
- •6. Previous invasive or non-invasive malignancy except:
- •(i) Ductal Carcinoma in Situ (DCIS) of the breast where treatment consisted of resection alone, (ii) cervical carcinoma in situ where treatment consisted of resection alone, (iii) basal cell or squamous cell carcinoma where treatment consisted of resection alone or radiotherapy, (iv) superficial bladder carcinoma where treatments consisted of resection alone or with a single installation of intracescical chemotherapy or with BCG treatment, (v) other cancers where the patient has been disease-free for at least 3 years and treatment was with curative intent and (vi) other cancers wih very low potential for recurrence can be discussed with the CI or his approved representative through the Glasgow CRUK Clinical Trials Unit where eligibility will be considered on an individual basis
- •7. Known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency
- •8. Known untreated coeliac disease (may be enrolled if diet controlled), untreated chronic inflammatory bowel disease or other cause of malabsorption or intestinal obstruction
- •9. Grade = 2 peripheral neuropathy
- •10. Administration of any investigational drug within 28 days or 5 half-lives, whichever is longer, prior to receiving the first dose
- •of trial treatment.
- •11. Previous hypersensitivity to platinum salts
- •12. Patients with clinically significant, active infections, or any other serious medical condition in which chemotherapy is contraindicated will be excluded
- •13. Patients with untreated vitamin B12 deficiency are excluded from receiving folinic acid as part of their chemotherapy regimen. However, these patients may be eligible for treatment with capecitabine fluoropyrimidine therapy, where no folinic acid is administered as part of the treatment regimen
- •14. Patients with clinically significant sensorineural hearing impairment are excluded from receiving oxaliplatin but will be eligible for the fluoropyrimidine monotherapy provided as a clinician’s choice for patients in group 1 randomised to either observation or chemotherapy
- •15. Any patient receiving treatment with brivudine, sorivudine and analogues
- •Previous participant exclusion criteria:
- •1. Non-adenocarcinoma histology of small bowel tumour which includes but is not confined to lymphoma, GIST, carcinoid or other neuroendocrine tumour, squamous carcinoma, melanoma or sarcoma
- •2. Previous neo-adjuvant chemo(radio)therapy for SBA
- •3. Clinically significant cardiovascular disease (i.e. active or < 12 months since cerebrovascular accident, myocardial infarction, unstable angina, New York Heart Association [NYH
研究者
相似试验
已完成
不适用
A clinical trial to study the effect of an additional procedure named basal cisternostomy in head injury patients planned for decompressive craniectomyCTRI/2022/04/042144King Georges Medical University100
尚未招募
不适用
A study to assess effectiveness of hydrogel and honey in treatment of diabetic foot ulcer among diabetic patients residing in rural areas of nelloreCTRI/2020/12/030103arayana College Of Nursing
尚未招募
不适用
A study to know the efficacy of adjuvant IgM in reducing mortality of very low birth weight newborns with sepsisCTRI/2022/09/045566Dr Rinku Saini
已完成
不适用
A study to investigate the benefit of adjuvant chemotherapy following resection of localised intermediate grade gastro-intestinal lymphoma and to assess the effect of depth of penetration of the tumour on survivalymphoma (non-Hodgkin's)Lymphoma (non-Hodgkin's)CancerISRCTN78467637Cancer Research UK (CRUK) (UK)
尚未招募
2 期
Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observatioNL-OMON50102niversity Hospital Essen30